Core Viewpoint - The article discusses the strategic transformation of Chen Li Ji, a 425-year-old traditional Chinese medicine brand, focusing on its integration of Chen Pi (dried tangerine peel) into the health industry, digital transformation, and rural revitalization efforts [1][2][4]. Group 1: Strategic Initiatives - Chen Li Ji launched the Chen Pi Cultural Festival themed "Sailing Against the Wind, Living Forever," marking its 425th anniversary and announcing the "Chen Pi Health" strategic plan [3][4]. - The company aims to leverage Chen Pi as a pivotal element to drive its growth in the health industry, digital transformation, and rural revitalization [5][12][54]. Group 2: Industry Context - The Chen Pi industry is experiencing unprecedented growth opportunities, with the New Hui district reporting a planting area of approximately 143,000 acres and a fresh fruit output of 180,000 tons in 2024 [16][17]. - The total output value of the Chen Pi industry is estimated at 26.018 billion yuan, providing employment and income increases for over 70,000 people, with farmers seeing an average income increase of about 22,000 yuan [18]. Group 3: Policy Support - The Chinese government has issued policies to promote the inheritance and innovation of traditional Chinese medicine, which supports the development of the Chen Pi industry [20][21][28]. - Chen Li Ji's new Chen Pi industrialization planting base was included in the second batch of Guangdong Province's traditional Chinese medicine industrialization base list in 2021, reflecting direct benefits from these policies [28][30]. Group 4: Consumer Trends - There is a notable shift in consumer demographics towards younger generations, with individuals under 35 years old making up 35.9% of the traditional health demand group [33]. - The health service industry is projected to reach a total scale of 16 trillion yuan by 2030, with the health and wellness market already valued at 708.2 billion yuan in 2022 and continuing to grow [34][35]. Group 5: Product Development - Chen Li Ji has expanded its product line from traditional Chinese medicine to include various health products such as aged Chen Pi, Chen Pi tea, and other health foods, catering to modern consumer preferences [54][78]. - The company has established a digital platform for the Chen Pi industry, integrating blockchain technology for traceability and quality assurance, addressing long-standing trust issues in the industry [68][76]. Group 6: Cultural Integration - Chen Li Ji is promoting cultural integration through events like the Chen Pi Cultural Festival and creative cultural projects, transforming traditional Chen Pi culture into appealing elements for younger consumers [80][83]. - The company has created an immersive cultural experience at its museum in Guangzhou, allowing urban consumers to engage with Chen Pi culture in a familiar setting [86][90].

Core Viewpoint - The company, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., is set to hold a Q3 2025 performance briefing on November 28, 2025, to discuss its operational results and financial status with investors [2][3]. Group 1: Meeting Details - The performance briefing will take place on November 28, 2025, from 16:00 to 17:00 [4]. - The meeting will be held at the Shanghai Stock Exchange Roadshow Center, accessible via the website: https://roadshow.sseinfo.com/ [4]. - The format of the meeting will be an interactive online session, allowing for real-time communication with investors [3][4]. Group 2: Participation Information - Investors can participate in the briefing by logging into the Shanghai Stock Exchange Roadshow Center on the scheduled date and time [5]. - Questions can be submitted by investors from November 21, 2025, to November 27, 2025, through the "Pre-Question Collection" section on the website or via the company's email [5]. - The company will address commonly asked questions during the briefing [5]. Group 3: Attendees - Key personnel attending the briefing include the Executive Director and General Manager, Mr. Li Hong, Independent Director Mr. Huang Longde, Board Secretary Ms. Huang Xuezheng, and Chief Financial Officer Ms. Liu Fei [4].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出的。 茲刊載廣州白雲山醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(www.sse.com.cn)刊登的 本公司關於召開2025年第三季度業績說明會的公告之中文全文，僅供參考。 廣州白雲山醫藥集團股份有限公司 董事會 中國廣州，2025年11月20日 於本公告日，本公司董事會成員包括執行董事李小軍先生、陳傑輝先生、程寧女士、程洪進先生、 唐和平先生與黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 证券代码：600332 证券简称：白云山 公告编号：2025-080 广州白云山医药集团股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、 说明会召 ...

Group 1 - The Artemisinin concept index rose by 0.31%, ranking 10th among concept sectors, with three stocks increasing in value, including Delong Huineng, Rundu Co., and Haizheng Pharmaceutical, which rose by 4.35%, 0.87%, and 0.19% respectively [1] - The leading decliners in the sector included Fosun Pharma, New Hecheng, and Baiyunshan, which fell by 1.23%, 0.36%, and 0.34% respectively [1] Group 2 - The main capital flow analysis indicates a net outflow of 176 million yuan from the Artemisinin concept sector, with only one stock, Delong Huineng, experiencing a net inflow of 8.0428 million yuan [2] - The capital flow rankings for the Artemisinin concept show that Delong Huineng had a trading volume of 4.35% and a turnover rate of 13.19%, while other stocks like Kunming Pharmaceutical Group and Rundu Co. had net outflows of 1.72 million yuan and 3.06 million yuan respectively [2][3]

证券代码：600332 证券简称：白云山 公告编号：2025-080 广州白云山医药集团股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 广州白云山医药集团股份有限公司（以下简称"公司"）已于 2025 年 10 月 28 日发布公司 2025 年第三季度报告，为便于广大投资者更 全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计 划于 2025 年 11 月 28 日（星期五）下午 16:00-17:00 举行 2025 年第 三季度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年第 会议召开时间：2025 年 11 月 28 日(星期五)下午 16:00-17:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资 ...

来源：新浪证券-红岸工作室 11月19日，白云山跌0.94%，成交额1.66亿元。两融数据显示，当日白云山获融资买入额1376.71万元， 融资偿还1548.14万元，融资净买入-171.43万元。截至11月19日，白云山融资融券余额合计8.31亿元。 分红方面，白云山A股上市后累计派现109.06亿元。近三年，累计派现43.59亿元。 机构持仓方面，截止2025年9月30日，白云山十大流通股东中，中国证券金融股份有限公司位居第四大 流通股东，持股4727.80万股，持股数量较上期不变。香港中央结算有限公司位居第五大流通股东，持 股2001.09万股，相比上期减少2043.72万股。华泰柏瑞沪深300ETF（510300）位居第七大流通股东，持 股1214.03万股，相比上期减少49.56万股。易方达沪深300医药ETF（512010）位居第八大流通股东，持 股881.01万股，相比上期减少271.42万股。易方达沪深300ETF（510310）位居第十大流通股东，持股 865.06万股，相比上期减少28.60万股。 融券方面，白云山11月19日融券偿还9400.00股，融券卖出0.00股，按当日收盘价计算， ...

每经AI快讯，天眼查工商信息显示，近日，王老吉关联公司广州王老吉大健康产业有限公司发生工商变更，注册资本由9亿元人民币增至10亿元人民币，增 幅约11%，同时发生高管变更。广州王老吉大健康产业有限公司成立于2012年2月，法定代表人为陈昆南，经营范围包括食用农产品零售、土地使用权租 赁、非居住房地产租赁等。股东信息显示，该公司由白云山（600332）（600332）全资持股。 | 大限台 | 都在用的商业查询工具 | | 查公司 查老板 查关系 查风险 | | | --- | --- | --- | --- | --- | | | 国家中小企业发展子基金旗下机构 | | × 天眼一下 广州王老吉大健康产业有限公司 | 船 应用 ▼ 商务合作 · | | 基本信息 122 | | 法律诉讼 71 | 经营风险 1 经营信息 999+ | 公司发展 133 知识 | | 变更记录 54 ○ ● | | | | 变更项目 - | | 序号 变更日期 | | 变更项目 | 变更前 | | | 1 2025-11-17 | | 章程备案 | 方达锋 | 准予章程备案 石洪超 【新讲】 | | | | | 陈昆南 翁少全 ...

天眼查工商信息显示，11月17日，王老吉关联公司广州王老吉大健康产业有限公司发生工商变更，注册 资本由9亿人民币增至10亿人民币，增幅约11%，同时发生高管变更。广州王老吉大健康产业有限公司 成立于2012年2月，法定代表人为陈昆南，经营范围包括食用农产品零售、土地使用权租赁、非居住房 地产租赁等。股东信息显示，该公司由白云山（600332）全资持股。 ...

会上，白云山稀核健康与全球医疗科技巨头GE医疗签署战略合作协议，双方将致力在精准医疗与核医 学领域的发展与创新，为充分发挥白云山稀核健康在放射性药物研发、生产与管理专业优势，以及GE 医疗深厚的技术沉淀，推动医学影像前沿技术的提升及转化，共同引领核医学诊疗一体化的发展。此次 合作既是广药集团"科技化""国际化"战略的具体实践，也是跨界资源整合、推动产业升级的重要探索。 白云山稀核健康此次发布的完全自主知识产权医用放射性核素一体化解决方案，成功攻克固体靶系统与 分离纯化技术壁垒，构建了从辐照到核素制备的全链条技术体系；同步推出的镓-68、锆-89、铼-186与 铜-64四大核心医用核素，涵盖精准诊断、靶向治疗及诊疗一体化方向，标志着广药集团已能完全自 主、稳定地制备上述四种关键医用放射性核素以及在多核素药物研发平台的建设上取得了决定性突破。 中证报中证网讯（王珞）11月18日，2025年广药集团、广药白云山（600332）战略合作研讨会在南京举 办。大会汇聚合作伙伴、行业专家及企业代表等430余位嘉宾，搭建起覆盖医药大健康全产业链的高端 对话与资源对接平台，集中发布了广药集团创新战略、创新成果与合作规划，其中核 ...

Policy Developments - The National Medical Products Administration (NMPA) is focusing on the quality supervision of selected drugs in centralized procurement, emphasizing the importance of quality safety and compliance in production [1] - The NMPA will implement comprehensive production inspections and product sampling for selected drugs, optimizing work mechanisms and exploring risk monitoring [1] - The NMPA acknowledges the development of the medical device industry in Chongqing and stresses the need for a robust quality safety responsibility system [2] Drug and Device Approvals - Baiyunshan's subsidiary Zhongyi Pharmaceutical received a registration certificate for the traditional medicine An Gong Niu Huang Wan from Vietnam's Ministry of Health, aiding market expansion [3] - Huyou Pharmaceutical announced that its subsidiary Seacross Pharmaceuticals Ltd. received marketing approvals for multiple products from regulatory authorities in Pakistan, the UK, and North Macedonia [4] - Zhifei Biological's recombinant herpes zoster vaccine (ZFA01) clinical trial application has been accepted by the NMPA, which may enhance vaccine efficacy [5] Capital Market Activities - Puluo Pharmaceutical plans to repurchase shares worth between RMB 180 million and RMB 360 million, with a maximum price of RMB 23 per share [6][7] - Sinovac Biotech received a delisting notice from NASDAQ due to failure to submit its annual report by the deadline, with potential trading suspension imminent [8] Industry Developments - Researchers published a detailed immune response map following pig kidney transplants in brain-dead patient models, identifying key factors for transplant success [9] - Haizheng Pharmaceutical's subsidiary plans to collaborate with the East China Institute for the biomanufacturing of heparin, with a project budget not exceeding RMB 120 million [10] Public Sentiment Alerts - Guangyuyuan announced the resignation of Vice President Wang Junbo due to work adjustments, effective immediately [11] - Medici's shareholder Chen Guoxing plans to reduce his stake by up to 1.64% through trading methods due to personal financial needs [12]